Market Closed -
Hong Kong S.E.
01:38:42 28/06/2024 pm IST
|
5-day change
|
1st Jan Change
|
6.44
HKD
|
+2.71%
|
|
+6.10%
|
-14.36%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
22,926
|
15,136
|
13,359
|
17,878
|
16,394
|
14,116
|
-
|
-
|
Enterprise Value (EV)
1 |
23,645
|
14,959
|
13,120
|
20,196
|
18,543
|
14,946
|
13,117
|
11,859
|
P/E ratio
|
23.8
x
|
18
x
|
8.54
x
|
9.91
x
|
11
x
|
7.87
x
|
7.16
x
|
6.46
x
|
Yield
|
-
|
-
|
3.78%
|
1.24%
|
3.38%
|
3.52%
|
4.07%
|
3.44%
|
Capitalization / Revenue
|
4.31
x
|
2.71
x
|
2.09
x
|
2.61
x
|
2.1
x
|
1.62
x
|
1.49
x
|
1.37
x
|
EV / Revenue
|
4.45
x
|
2.68
x
|
2.06
x
|
2.94
x
|
2.37
x
|
1.72
x
|
1.39
x
|
1.15
x
|
EV / EBITDA
|
11.8
x
|
9.31
x
|
5.99
x
|
7.22
x
|
6.7
x
|
5.25
x
|
4.25
x
|
3.5
x
|
EV / FCF
|
16.9
x
|
33.1
x
|
23.9
x
|
15.9
x
|
12.7
x
|
10.9
x
|
6.9
x
|
5.73
x
|
FCF Yield
|
5.93%
|
3.02%
|
4.19%
|
6.29%
|
7.86%
|
9.21%
|
14.5%
|
17.4%
|
Price to Book
|
2.38
x
|
1.41
x
|
1.1
x
|
1.36
x
|
1.19
x
|
0.94
x
|
0.84
x
|
0.75
x
|
Nbr of stocks (in thousands)
|
25,39,974
|
25,43,601
|
25,22,355
|
24,38,845
|
23,98,563
|
23,55,211
|
-
|
-
|
Reference price
2 |
9.026
|
5.950
|
5.296
|
7.330
|
6.835
|
5.994
|
5.994
|
5.994
|
Announcement Date
|
30/03/20
|
30/03/21
|
28/03/22
|
21/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5,318
|
5,588
|
6,382
|
6,859
|
7,816
|
8,688
|
9,462
|
10,301
|
EBITDA
1 |
2,005
|
1,606
|
2,190
|
2,796
|
2,768
|
2,846
|
3,088
|
3,393
|
EBIT
1 |
1,652
|
1,503
|
1,642
|
1,658
|
1,915
|
2,517
|
2,731
|
3,006
|
Operating Margin
|
31.06%
|
26.89%
|
25.73%
|
24.18%
|
24.51%
|
28.97%
|
28.87%
|
29.18%
|
Earnings before Tax (EBT)
1 |
1,223
|
979.1
|
1,869
|
2,274
|
1,978
|
2,397
|
2,629
|
2,841
|
Net income
1 |
973.7
|
835.8
|
1,651
|
1,915
|
1,549
|
1,953
|
2,149
|
2,305
|
Net margin
|
18.31%
|
14.96%
|
25.87%
|
27.92%
|
19.82%
|
22.48%
|
22.71%
|
22.37%
|
EPS
2 |
0.3800
|
0.3300
|
0.6200
|
0.7400
|
0.6200
|
0.7618
|
0.8376
|
0.9278
|
Free Cash Flow
1 |
1,403
|
451.6
|
549.2
|
1,271
|
1,458
|
1,376
|
1,901
|
2,069
|
FCF margin
|
26.38%
|
8.08%
|
8.61%
|
18.53%
|
18.66%
|
15.84%
|
20.1%
|
20.08%
|
FCF Conversion (EBITDA)
|
69.96%
|
28.12%
|
25.08%
|
45.44%
|
52.67%
|
48.35%
|
61.57%
|
60.97%
|
FCF Conversion (Net income)
|
144.06%
|
54.03%
|
33.26%
|
66.36%
|
94.12%
|
70.44%
|
88.49%
|
89.77%
|
Dividend per Share
2 |
-
|
-
|
0.2000
|
0.0912
|
0.2314
|
0.2112
|
0.2442
|
0.2060
|
Announcement Date
|
30/03/20
|
30/03/21
|
28/03/22
|
21/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
2,675
|
2,695
|
2,892
|
3,110
|
3,275
|
3,091
|
3,768
|
3,784
|
4,032
|
4,318
|
4,620
|
4,498
|
5,254
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
915.3
|
727
|
802.5
|
855.8
|
1,301
|
614.8
|
1,459
|
1,307
|
1,496
|
1,494
|
Operating Margin
|
-
|
-
|
-
|
29.43%
|
22.2%
|
25.96%
|
22.71%
|
34.38%
|
15.25%
|
33.79%
|
28.3%
|
33.25%
|
28.43%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.2500
|
0.2700
|
0.0600
|
0.3400
|
0.2800
|
0.3700
|
0.3700
|
0.3900
|
0.2300
|
0.4400
|
0.3900
|
0.4500
|
0.4400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
17/08/20
|
30/03/21
|
25/08/21
|
28/03/22
|
24/08/22
|
21/03/23
|
24/08/23
|
20/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
719
|
-
|
-
|
2,318
|
2,148
|
830
|
-
|
-
|
Net Cash position
1 |
-
|
177
|
239
|
-
|
-
|
-
|
999
|
2,257
|
Leverage (Debt/EBITDA)
|
0.3587
x
|
-
|
-
|
0.8291
x
|
0.776
x
|
0.2918
x
|
-
|
-
|
Free Cash Flow
1 |
1,403
|
452
|
549
|
1,271
|
1,458
|
1,376
|
1,901
|
2,069
|
ROE (net income / shareholders' equity)
|
10.7%
|
8.23%
|
15.1%
|
15.2%
|
11.5%
|
12.6%
|
12.6%
|
12.3%
|
ROA (Net income/ Total Assets)
|
6.8%
|
5.15%
|
8.95%
|
9.3%
|
6.79%
|
8.23%
|
8.38%
|
8.44%
|
Assets
1 |
14,324
|
16,244
|
18,445
|
20,601
|
22,817
|
23,720
|
25,652
|
27,318
|
Book Value Per Share
2 |
3.800
|
4.220
|
4.810
|
5.400
|
5.750
|
6.400
|
7.110
|
8.010
|
Cash Flow per Share
2 |
0.7400
|
0.4900
|
0.5700
|
0.8200
|
0.8500
|
0.7700
|
1.170
|
1.080
|
Capex
1 |
471
|
893
|
1,029
|
910
|
625
|
905
|
842
|
1,089
|
Capex / Sales
|
8.86%
|
15.98%
|
16.13%
|
13.26%
|
7.99%
|
10.42%
|
8.9%
|
10.57%
|
Announcement Date
|
30/03/20
|
30/03/21
|
28/03/22
|
21/03/23
|
20/03/24
|
-
|
-
|
-
|
Last Close Price
5.994
CNY Average target price
6.959
CNY Spread / Average Target +16.11% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.36% | 1.94B | | +2.99% | 95.18B | | -4.34% | 37.55B | | -10.41% | 33.75B | | +75.79% | 28.2B | | -14.61% | 15.63B | | -3.46% | 13.63B | | -12.31% | 11.5B | | +184.77% | 10.81B | | -54.13% | 9.23B |
Biopharmaceuticals
|